Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Uveal Melanoma 1Recurrence 1Ovarian Neoplasms 1Multiple Myeloma 1Fallopian Tube Neoplasms 1Advanced Cancer 1

Interventions

pembrolizumab 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3Radiosurgery 2MART-1 Antigen 2CTLA-4 Antigen 2ulixertinib 1sotrastaurin 1siremadlin 1relatlimab 1pentetreotide 1oblimersen 1incomplete Freund's adjuvant 1fotemustine 1fludarabine phosphate 1fludarabine 1entrectinib 1defactinib 1binimetinib 1benzamide 1aldesleukin 1aflibercept 1Valacyclovir 1Toll-Like Receptor 1 1TYRP1 protein, human 1Sunitinib 1Standard of Care 1RO5126766 1RNA, Messenger 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uveal Melanoma × relatlimab × Clear all
NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

TriSalus Life Sciences, Inc.

Phase 1 Terminated
67 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡